Published • loading... • Updated
Takeda’s QDENGA becomes first dengue vaccine approved in India
The vaccine covers all four dengue serotypes and needs no pre-vaccination screening, with Takeda citing approval in 43 countries and more than 32 million doses distributed globally.
- On Monday, the Drug Controller General of India approved QDENGA, Takeda Pharmaceutical's dengue vaccine, marking the first such authorization in India for individuals aged 4 to 60 years.
- India accounts for nearly one-third of the global dengue burden, with reported cases in the country increasing 11-fold over the past two decades, creating urgent public health demand.
- The vaccine is administered in two 0.5 ml injections spaced three months apart and requires no pre-vaccination testing, allowing use regardless of prior dengue exposure.
- World Health Organization pre-qualification confirms the vaccine meets global safety standards, enabling procurement by UNICEF and the Pan American Health Organization to expand access.
- Takeda partnered with Biological in 2024 to establish manufacturing capacity for 50 million doses annually, supporting the company's goal of producing 100 million doses globally every year.
Insights by Ground AI
49 Articles
49 Articles
India approved for the first time the marketing of a dengue vaccine. Japanese-made Qdenga immunizer was authorized, announced on Tuesday (21) the country's Ministry of Health. Instead of a cruise, a baby: a US couple discovers pregnancy when entering labor hours before the 'walking Ebola' trip: why the outbreak in the Congo is so difficult to contain According to the World Health Organization (WHO), half of the world's population is currently at…
·Rio de Janeiro, Brazil
Read Full Article
Free Malaysia Today News+2 Reposted by 2 other sources
India approves first dengue vaccine
India's Central Drugs Standard Control Organisation (CDSCO) approved the vaccine for people between the ages of four and 60 after reviewing its quality, safety and efficacy.
·Petaling Jaya, Malaysia
Read Full Article
Coverage Details
Total News Sources49
Leaning Left4Leaning Right15Center3Last UpdatedBias Distribution68% Right
Bias Distribution
- 68% of the sources lean Right
68% Right
L 18%
14%
R 68%
Factuality
To view factuality data please Upgrade to Premium
